A practical guide to ICH Q5A(R2) Viral Safety, covering cell-substrate risk, adventitious-agent testing, NGS, viral clearance, platform validation, and CTD Module 3.

Container closure systems are part of biologic product quality, sterile-barrier assurance, and dose delivery. This guide connects CCIT, extractables and leachables, vial and prefilled-syringe risks, stability, shipping, in-use studies, and CTD Module 3.

A passing release result cannot independently support long-term shelf life. This guide connects ICH Q5C with real-time, accelerated, shipping, in-use, and ongoing stability strategies.

A validated method may still fail to support product decisions. This guide connects ICH Q2(R2), Q14, ATP, potency assays, method transfer, and lifecycle monitoring.

Are three batches enough? Explore the process validation lifecycle, PPQ evidence, and continued monitoring through a hypothetical monoclonal antibody program.

Biologics processes continue to evolve after approval. This guide explains how ICH Q12 uses Established Conditions, PACMPs, PLCM documents, and the PQS to make post-approval CMC changes more predictable and risk-based.

Biologics quality cannot rely on release testing alone. This guide explains how to build an integrated strategy across materials, manufacturing, analytics, specifications, and continued monitoring.

The bottleneck in In Vivo CAR T may be delivery rather than the CAR itself. This article examines ERTLNP, T-cell activation, mTOR signaling, CMC implications, and the emerging 2026 clinical landscape.

Passing release specifications does not establish comparability. Learn how ICH Q5E integrates risk assessment, analytical characterization, stability, process data, and regulatory strategy.

A biologics specification is not simply a table of tests and limits. This guide explains how ICH Q6B connects product characterization, critical quality attributes, release testing, acceptance criteria, CTD Module 3, and the evolving direction of Q6(R1).

Biologics CMC Regulatory Framework: Executive Summary If you only have three minutes, remember these five points: Biologics CMC is not a single regulation. It is a lifecycle framework connecting the product, manufacturing process, analytical methods, control strategy, and pharmaceutical quality system. ICH provides a shared scientific language. FDA and European authorities apply those principles through their own laws, submission pathways, and post-approval change procedures.